Top Page
Next Science Ltd
(OTC:NXS)
Next Science Ltd (NXS) vs. iShares MSCI Australia ETF (EWA)
Next Science Ltd Business Overview & Revenue Model
Next Science Ltd Earnings Call Summary
Next Science Ltd Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 22.82M | 22.18M | 16.90M | ― | ― |
| Gross Profit | 18.44M | 16.23M | 11.90M | ― | ― |
| EBITDA | -9.03M | -14.42M | -17.02M | ― | -13.18M |
| Net Income | -10.59M | -24.51M | -18.30M | ― | -13.27M |
Balance Sheet | |||||
| Total Assets | 9.21M | 17.90M | 18.37M | 13.67M | 23.49M |
| Cash, Cash Equivalents and Short-Term Investments | 1.67M | 9.28M | 7.54M | ― | 15.24M |
| Total Debt | 2.49M | 961.97K | 1.80M | ― | ― |
| Total Liabilities | 5.77M | 5.08M | 6.52M | ― | ― |
| Stockholders Equity | 3.44M | 12.82M | 11.85M | 10.73M | 18.80M |
Cash Flow | |||||
| Free Cash Flow | -8.55M | -15.94M | -17.69M | ― | -14.03M |
| Operating Cash Flow | -7.96M | -15.06M | -17.01M | ― | -13.26M |
| Investing Cash Flow | -589.22K | -884.50K | -686.23K | ― | ― |
| Financing Cash Flow | 1.75M | 20.11M | 14.78M | ― | 11.93M |
Next Science Ltd Technical Analysis
Next Science Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | AU$49.01M | 20.88 | 4.85% | ― | 5.76% | -79.76% | |
50 Neutral | AU$2.60B | 3.65 | -58.14% | 2.69% | 36.37% | 13.78% | |
47 Neutral | AU$40.97M | ― | -130.18% | ― | 3.37% | 47.32% | |
46 Neutral | AU$37.14M | ― | -19.31% | ― | 72.25% | 43.66% | |
45 Neutral | AU$80.55M | ― | -45.40% | ― | 13.61% | -55.12% | |
41 Neutral | AU$19.45M | ― | -218.38% | ― | -14.30% | 29.69% |
Next Science Ltd Corporate Events
Next Science Limited reported a 10% decline in product sales for the second quarter of FY25 compared to the previous year, with sales totaling US$5.2 million. Despite strong growth in direct sales of XPERIENCE and BLASTX, the company faced challenges in the Durable Medical Equipment (DME) channel, impacting overall sales. The company also announced a binding asset purchase agreement with Demetra Holdings S.p.A., subject to shareholder approval, which could influence its market positioning and operations.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
Next Science Limited has announced a General Meeting scheduled for August 28, 2025, to discuss the proposed asset purchase agreement with Demetra, which involves the sale of Next Science’s main undertaking. This transaction requires shareholder approval as per Listing Rule 11.2, and the meeting will be conducted both in-person and virtually. The outcome of this meeting could significantly impact the company’s operations and market positioning, as it involves a major asset sale.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
Next Science Limited announced a change in the director’s interest, with Managing Director Harry Thomas Hall, IV acquiring 465,131 ordinary fully paid shares as part of an equity settlement. This change reflects the issuance of new shares in settlement of tranche 2 of the Sign-On Rights, approved by shareholders at the company’s 2024 AGM, indicating a strategic move to align executive interests with company performance.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
Next Science Ltd has issued 465,131 ordinary shares to its Managing Director and CEO, I.V. Hall, as part of the settlement for tranche 2 of the Sign-On Rights. This issuance was conducted without disclosure to investors under the Corporations Act, and the company confirms compliance with relevant legal provisions, indicating a transparent and regulated approach to executive compensation.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
Next Science Limited announced that all resolutions were passed at its 2025 Annual General Meeting, as determined by a poll. This successful meeting outcome reflects positively on the company’s governance and may reinforce stakeholder confidence, potentially impacting its market positioning favorably.
Next Science Limited held its 2025 Annual General Meeting, where the Chair and CEO highlighted significant operational improvements and strategic advancements made in 2024. The company reduced its cash burn by US$7 million, improved margins, and achieved cash flow positivity for two non-consecutive months. With a US$5 million loan facility secured, Next Science is well-positioned for future growth. Clinical research published in 2024 demonstrated the effectiveness of its products, BLASTX and XPERIENCE, in reducing infections and inflammation, contributing to lower healthcare costs. The company also continued its large-scale study on periprosthetic joint infections, enrolling 1,220 patients by the end of 2024. Despite a decline in the Durable Medical Equipment channel, Next Science achieved record revenue of US$22.8 million, driven by strong direct and partner sales.